Back to news

Alamar Biosciences Highlights NULISA Data in 46 Presentations at CTAD 2026, Including 10 Oral Presentations

Globe Newswire•16/11/2026•06:00 ET
0

Key Highlights

  • ➤46 CTAD presentations feature Alamar’s NULISA data, including 10 oral presentations
  • ➤NULISA supports Alzheimer’s research spanning risk screening, trial enrollment and treatment response
  • ➤Brain-derived p-tau217 outperformed 328 plasma proteins across amyloid, tau and cognitive measures
  • ➤NULISA measured therapeutic-response biomarkers from Johnson & Johnson’s Phase 2 Autonomy trial
  • ➤Ultrasensitive plasma eMTBR-tau advances blood-based assessment of tau pathology

Expert Statements

Yuling Luo, Founder, CEO and chair of Alamar Biosciences

“Given the advances in blood-based biomarkers for diagnosing Alzheimer's, research is shifting toward treatment, and that shift depends on measuring many proteins in blood with enough sensitivity to see small changes over time”

Yuling Luo, Founder, CEO and chair of Alamar Biosciences

“This year's CTAD presentations show researchers using NULISA to screen patients, enrich clinical trials and follow therapeutic response, often in the same study.”

Yuling Luo, Founder, CEO and chair of Alamar Biosciences

“The breadth of this work reinforces NULISA's position as the leading multiplex platform in Alzheimer’s research.”

Yuling Luo, Founder, CEO and chair of Alamar Biosciences

“We are grateful to our collaborators for this work and for what it means for the patients who will benefit from it.”

Nicholas Ashton, Senior director of the Fluid Biomarker Laboratory at Banner Health

“Blood biomarkers have transformed how we diagnose Alzheimer’s disease and conduct clinical trials.”

Nicholas Ashton, Senior director of the Fluid Biomarker Laboratory at Banner Health

“With the development of an ultrasensitive singleplex assay for plasma eMTBR-tau, we are moving closer to characterizing the two fundamental pathological hallmarks of Alzheimer’s disease—amyloid plaques and tau tangles—through a simple blood sample.”

Nicholas Ashton, Senior director of the Fluid Biomarker Laboratory at Banner Health

“This represents an important step toward more precise disease staging and monitoring.”

Nicholas Ashton, Senior director of the Fluid Biomarker Laboratory at Banner Health

“Beyond these core pathologies, the ability to measure hundreds of proteins simultaneously using sensitive multiplex platforms such as NULISA offers an exciting opportunity to deepen our understanding of disease biology, identify additional pathological processes, and ultimately improve diagnostic and prognostic accuracy.”

Nicholas Ashton, Senior director of the Fluid Biomarker Laboratory at Banner Health

“Together, these approaches could transform how we characterize Alzheimer’s disease and guide future clinical trials and treatment strategies.”

Fremont, Calif., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced that data generated with its NULISA™ precision proteomic platform will be featured in 46 presentations, including 10 oral presentations, at the Clinical Trials on Alzheimer's Disease (CTAD) conference, taking place November 16 to 19, 2026, in Boston.

The presentations come from researchers at academic centers, clinical research institutes and biopharmaceutical companies in the United States, Europe and Asia. Together they show NULISA being used at each stage of Alzheimer's research, from identifying who is at risk and enrolling the right patients in clinical trials to measuring how patients respond to treatment.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in